aTyr Pharma (NASDAQ:ATYR) Sees Large Volume Increase - Here's Why

Key Points

• aTyr Pharma shares saw a significant trading-volume increase, with about 111,433 shares changing hands—78% above the average daily volume. The stock traded at $5.36, up from its prior close of $5.136.
• Analyst sentiment is mixed but leans positive, with ratings ranging from Strong Buy to Sell and an overall “Moderate Buy” consensus. The company also reported a quarterly loss of $4.40 per share, beating the expected loss of $4.86.
• Bank of America increased its aTyr stake by 139.6% in the first quarter, while institutional investors and hedge funds collectively own 61.72% of the company. aTyr’s lead candidate, efzofitimod, is being developed to regulate immune responses in the lungs.

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report) saw an uptick in trading volume on Thursday. Approximately 111,433 shares were traded during mid-day trading, an increase of 78% from the average daily volume of 62,656 shares. The stock last traded at $5.36 and had previously closed at $5.1360.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Weiss Ratings downgraded aTyr Pharma from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday, September 16th. Wall Street Zen upgraded shares of aTyr Pharma from a "sell" rating to a "hold" rating in a report on Sunday, July 12th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy".

aTyr Pharma Stock Performance

The stock has a market capitalization of $532.61 million, a P/E ratio of -8.71 and a beta of 0.91. The company's fifty day simple moving average is $0.35 and its two-hundred day simple moving average is $0.61.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The company reported ($4.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.86) by $0.46. On average, research analysts predict that aTyr Pharma, Inc. will post -0.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in aTyr Pharma stock. Bank of America Corp DE boosted its stake in shares of aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report) by 139.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 303,559 shares of the company's stock after acquiring an additional 176,859 shares during the period. Bank of America Corp DE owned 0.31% of aTyr Pharma worth $237,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 61.72% of the company's stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc NASDAQ: ATYR is a biotechnology company focused on developing therapies that modulate immune system activity. The company's research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr's lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.